CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland

  • June 2018 •
  • 124 pages •
  • Report ID: 5471678 •
  • Format: PDF
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland

High expenditure on pharmaceutical R&D and the presence of major pharmaceutical companies has propelled the growth of the Swiss healthcare industry.The increasing elderly population and associated disease burden are expected to drive the growth of the pharmaceutical market.

Switzerland holds second place following the US in terms of healthcare spending, when compared with healthcare costs.It spends approximately 11.65% of its GDP on healthcare.In 2015 pharmaceutical sales increased to $6.4 billion from $5.5 billion in 2010. The market is forecast to grow to $8.0 billion in 2022; at a CAGR of 3%.

In 2010, the medical device market in Switzerland was worth $2.4 billion, which increased to $3.1 billion in 2017. The main segments were in vitro diagnostics, cardiovascular devices, nephrology and urology devices, orthopedic devices and healthcare IT. The increasing elderly population and high investment in R&D expenditure are expected to drive the growth of pharmaceutical market.

More than a third of Swiss exports come from the pharmaceutical industry, making it a major contributor to the Swiss economy.In 2017, pharmaceutical exports amounted to $70.3 billion. In order to further support the growth and secure the country’s role as a leader in innovation, the Swiss government introduced the Innovation Park in 2016, with two hubs associated with the Federal Institutes of Technology.

The latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland", is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Switzerland.It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Switzerland.

Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

The report provides information on the healthcare, regulatory, and reimbursement landscape in Switzerland, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market (Octapharma, Basilea, Actelion, Novartis and Roche) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Roche Diagnostics, DePuy Synthes, Agfa and Coloplast)
- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Switzerland
- Porter’s five forces analysis for pharmaceutical and medical devices market of Switzerland
- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Swiss healthcare market.

Reasons to buy
This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the Swiss healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in the Swiss healthcare market.

We are very sorry, but an error occurred.
Please contact if the problem remains.